SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-13 |
| Reported value | $162,612,689 |
| Positions | 8 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | GLUE | Common Stock | $76,974,876 | 3,180,780 |
| Century Therapeutics, Inc. | IPSC | Common Stock | $29,806,967 | 12,166,109 |
| Jade Biosciences, Inc. | JBIO | Common Stock | $22,037,418 | 991,783 |
| Lenz Therapeutics, Inc. | LENZ | Common Stock | $15,091,124 | 2,656,888 |
| Contineum Therapeutics, Inc. | CTNM | Common Stock | $8,893,673 | 542,628 |
| CRISPR Therapeutics AG | CRSP | Common Shares | $8,117,243 | 148,831 |
| Skye Bioscience, Inc. | Unresolved | Common Stock | $1,391,941 | 2,007,704 |
| Tempest Therapeutics, Inc. | Unresolved | Common Stock | $299,447 | 269,772 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.